PMID: 9634805Jul 1, 1995Paper

Polyclonal preparations of anti-tetanus toxoid antibodies derived from a combinatorial library confer protection

Bio/technology
A B LangB M Stadler

Abstract

We have compared the in vivo therapeutic potential of anti-tetanus toxin (TT) human Fab antibodies derived from a combinatorial phage display library to established polyclonal and monoclonal reagents. The oligoclonality and fine specificity distribution of the synthetic anti-TT Fab preparations was comparable to the antibody spectrum present in the donor serum and the affinities determined for the synthetic phage-bound Fab (Phab) and soluble Fab were in the same range as their monoclonal and polyclonal counterparts. On a weight basis, the protective capacity of the new oligoclonal preparations in vivo (16.4 IU/100 micrograms Fab) was comparable to those of the best combinations of hybridoma derived human monoclonal antibodies, and far better than those exhibited by the polyclonal serum antibodies of the donor (0.29 IU/100 micrograms IgG) or by a standard commercial human tetanus immunoglobulin preparation. These data suggest that recombinant antibodies may become a safe and effective alternative to human plasma-derived immunoglobulins for passive immunization.

References

Nov 11, 1992·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasD R Burton
Dec 1, 1992·Immunological Reviews·H R HoogenboomG Winter
Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S L ZebedeeR A Lerner
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasE Norrby
Nov 20, 1992·Science·R A LernerC F Barbas
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D R BurtonR A Lerner
Sep 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasS J Benkovic
May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·A S KangR A Lerner
Aug 15, 1991·Nature·T ClacksonG Winter
Jan 24, 1991·Nature·G Winter, C Milstein
Aug 31, 1989·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·G P Winter
Apr 1, 1987·Journal of Biological Standardization·O SimonsenI Heron
May 1, 1994·European Journal of Immunology·M VogelB M Stadler
May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R A WilliamsonD R Burton
Feb 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·J E CroweD R Burton
Feb 10, 1994·Journal of Immunological Methods·R J Owens, R J Young

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.